SCHEMBL8910979

SCHEMBL8910979

CNCC(CO)(CO)CO

nearest known ligand 0.35

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.35
TSHR P16473 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9352789 0.93 ALDH1A1 (0.35) ALDH1A1TSHR
SCHEMBL13004403 0.85 ALDH1A1 (0.30) ALDH1A1TSHR
SCHEMBL24490717 0.83
Water SCHEMBL28173589 0.83
SCHEMBL20007953 0.83
SCHEMBL2293158 0.78
SCHEMBL5013498 0.77 EPHX1 (0.32) ALDH1A1
SCHEMBL5090317 0.72 ALDH1A1 (0.39) ALDH1A1TSHR
SCHEMBL2319153 0.71
SCHEMBL27271966 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3421586-B1 IMMOBILIZED ENYMATIC REACTOR WATERS TECHNOLOGIES CORP (US) 2021-10-27 EP disclosed
US-20210239655-A1 DEVICE AND METHODS FOR PERFORMING SIZE EXCLUSION CHROMATOGRAPHY WATERS TECHNOLOGIES CORPORATION (US) 2021-08-05 US disclosed
US-20200216873-A1 IMMOBILIZED ENZYMATIC REACTOR WATERS TECHNOLOGIES CORPORATION (US) 2020-07-09 US disclosed
EP-3421586-A2 IMMOBILIZED ENYMATIC REACTOR Waters Technologies Corporation (US) 2019-01-02 EP disclosed
US-20180171379-A1 IMMOBILIZED ENZYMATIC REACTOR WATERS TECHNOLOGIES CORPORATION 2018-06-21 US disclosed
US-20180171379-A1 IMMOBILIZED ENZYMATIC REACTOR WATERS TECHNOLOGIES CORPORATION 2018-06-21 US disclosed
US-9890411-B2 Immobilized enzymatic reactor WATERS TECHNOLOGIES CORPORATION (US) 2018-02-13 US disclosed
US-9890411-B2 Immobilized enzymatic reactor WATERS TECHNOLOGIES CORPORATION (US) 2018-02-13 US disclosed
US-20140162298-A1 IMMOBILIZED ENZYMATIC REACTOR WATERS TECHNOLOGIES CORPORATION (US) 2014-06-12 US disclosed
US-20140162298-A1 IMMOBILIZED ENZYMATIC REACTOR WATERS TECHNOLOGIES CORPORATION (US) 2014-06-12 US disclosed
US-7312205-B2 Methods and compositions for inhibiting tumor growth NOVELIX PHARMACEUTICALS, INC. (US) 2007-12-25 US disclosed
US-20070258905-A1 Contrast Agents Endowed with High Relaxivity for Use in Magnetic Resonance Imaging (Mri) Which Contain a Chelating Moiety with Polyhydroxylated Substituents BRACCO IMAGING SPA (IT) 2007-11-08 US disclosed
US-20070258905-A1 Contrast Agents Endowed with High Relaxivity for Use in Magnetic Resonance Imaging (Mri) Which Contain a Chelating Moiety with Polyhydroxylated Substituents BRACCO IMAGING SPA (IT) 2007-11-08 US disclosed
US-7291713-B2 Branched polyalkylene glycols KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-11-06 US disclosed
US-7291713-B2 Branched polyalkylene glycols KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-11-06 US disclosed
US-20070134163-A1 Radiographic contrasting agents and radio-opaque polymeric materials for medical devices CORDIS US CORP 2007-06-14 US disclosed
US-5609851-A Compounds which can be used in contrast products for radiography GUERBET S A. (FR) 1997-03-11 US disclosed
WO-1993016983-A1 COMPOUNDS USED IN CONTRAST PRODUCTS FOR RADIOGRAPHY GUERBET S.A. (FR) 1993-09-02 WO disclosed
EP-0558395-A1 Compounds useful in contrast agents for radiography GUERBET S.A. (FR) 1993-09-01 EP disclosed
US-5057425-A Recombinant DNA cloning vector ELI LILLY AND COMPANY (US) 1991-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070134163-A1 Radiographic contrasting agents and radio-opaque polymeric materials for medical devices MYADM, PBRM1, RXFP3 ALDH1A1 3894/4885TSHR 1324/4885
US-20070258905-A1 Contrast Agents Endowed with High Relaxivity for Use in Magnetic Resonance Imaging (Mri) Which Contain a Chelating Moiety with Polyhydroxylated Substituents RXFP1, SLC5A7, SLC40A1 ALDH1A1 2843/4885TSHR 1132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.